共 26 条
Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients
被引:15
作者:
Busch, Jonas
[1
]
Magheli, Ahmed
[1
]
Leva, Natalia
[2
]
Hinz, Stefan
[1
]
Ferrari, Michelle
[2
]
Friedersdorff, Frank
[1
]
Fuller, Tom Florian
[1
]
Miller, Kurt
[1
]
Gonzalgo, Mark L.
[3
]
机构:
[1] Charite, Dept Urol, D-13353 Berlin, Germany
[2] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA
[3] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA
关键词:
Prostate cancer;
Prostatectomy;
Laparoscopy;
Robotic surgery;
Oncologic outcome;
Propensity score matching;
High risk;
CANCER;
RADIOTHERAPY;
EXPERIENCE;
CARCINOMA;
THERAPY;
SURGERY;
RATES;
STAGE;
MEN;
D O I:
10.1007/s00345-014-1270-0
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Comparative data related to the use of open and minimally invasive surgical approaches for the treatment of high-risk prostate cancer (PCa) remain limited. We determined outcomes of open radical prostatectomy (RRP), laparoscopic RP (LRP), and robot-assisted RP (RARP) in matched cohorts of patients with high-risk prostate cancer. A total of 805 patients with high-risk PCa [prostate-specific antigen (PSA) > 20 ng/mL, Gleason score a parts per thousand yen8, or clinical stage a parts per thousand yencT2c] were identified. A total of 407 RRP cases were propensity score (PS) matched 1:1 to 398 LRP or RARP cases to yield 3 cohorts (RARP, LRP, and RRP) of 110 patients each for analysis. PS matching variables included the following: age, clinical stage, preoperative PSA, biopsy Gleason score, surgeon experience, and nerve-sparing technique. Overall survival (OS) and recurrence-free survival (RFS) were compared with log-rank test. RFS predictor analysis was calculated within Cox regression models. Pathological Gleason scores < 7, =7, and > 7 were found in 3.3, 50.9, and 45.8 % of patients. There were no statistically significant differences for pathological stage and positive surgical margins between surgical techniques. Mean 3-year RFS was 41.4, 77.9, and 54.1 %, for RARP, LRP, and RRP, respectively (p < 0.0001 for RARP vs. LRP). There were no significant differences for mean estimated 3-year OS for patients treated with RARP, LRP, or RRP (95.4, 98.1, and 100 %). RARP demonstrated similar oncologic outcomes compared to RRP and LRP in a PS-matched cohort of patients with high-risk prostate cancer.
引用
收藏
页码:1411 / 1416
页数:6
相关论文